Norman Kim

Norman Kim has extensive experience in the pharmaceutical and biotechnology industry. Norman currently serves as the Vice President of Nonclinical Development at BlueRock Therapeutics since August 2021. Prior to this, they held the position of Senior Director of Nonclinical Safety at Magenta Therapeutics from November 2020 to August 2021. From July 2019 to September 2020, they worked at Relay Therapeutics as the Senior Director of Toxicology. Before that, they served as the Senior Director of Nonclinical Development at Immunovant, Inc. from August 2018 to July 2019. Norman also held senior positions at Roivant Sciences, Biogen, Inotek Pharmaceuticals Corporation, Sepracor Inc, Alkermes, and Arthur D. Little, with responsibilities ranging from preclinical development to toxicology to genetic toxicology.

Norman Kim holds a Master's Degree in Biomedical Sciences, specialized in Toxicology, from Northeastern University. Prior to that, they earned a Bachelor's Degree in Biology from the University of Rhode Island. In addition to their academic achievements, Norman also obtained certifications as a Diplomate from the American Board of Toxicology and as a European Registered Toxicologist from the UK Registered Toxicologist, Royal Society of Biology.